CFB and Parkinson disease: Recently, a double-blind, randomized, placebo-controlled phase I/IIa study was carried out in Sweden to assess the safety and tolerability of i.c.v. recombinant human PDGF-BB (rhPDGF-BB) administration in PD subjects [48].